- ISIN
- US6047491013
- CUSIP
- 604749101
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 18, 2019
Highlights
- Market Cap
- $6.46B
- Enterprise Value
- $6.46B
- EPS (TTM)
- -$14.43
- Total Revenue (TTM)
- $409.73M
- Gross Profit (TTM)
- -$422.68M
- EBITDA (TTM)
- -$771.51M
- Year Range
- $50.25 - $130.00
- Target Price
- $131.00
- ROA (TTM)
- -89.67%
- ROE (TTM)
- -329.43%
- Avg. Volume (1M)
- 611K
- Avg. Volume Value (1M)
- $72.48M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
MIRM Performance Chart
Mirum Pharmaceuticals, Inc. (MIRM) is up 34.1% since the beginning of the year. At $106 per share, MIRM is trading 18.5% below its 52-week high of $130. Investors who bought $1,000 worth of MIRM shares 5 years ago would now be looking at an investment worth $7,332.
Loading charts...
Compare this symbol against anything
Returns By Period
Mirum Pharmaceuticals, Inc. (MIRM) has returned 34.13% so far this year and 103.67% over the past 12 months.
Mirum Pharmaceuticals, Inc.
- 1D
- -5.90%
- 1M
- -15.64%
- 6M
- 2.64%
- YTD
- 34.13%
- 1Y
- 103.67%
- 3Y*
- 61.89%
- 5Y*
- 48.95%
- 10Y*
- —
- ALL TIME*
- 34.74%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
MIRM Monthly Returns History
Based on dividend-adjusted daily data since Jul 18, 2019, MIRM's average daily return is +0.21%, while the average monthly return is +5.06%. At this rate, an investment would double in approximately 1.2 years.
Historically, 54% of months were positive and 46% were negative. The best month was Dec 2019 with a return of +240.1%, while the worst month was Jan 2020 at -35.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 3 months.
On a daily basis, MIRM closed higher 51% of trading days. The best single day was Dec 16, 2019 with a return of +111.0%, while the worst single day was Dec 15, 2020 at -22.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 30.67% | -10.59% | 0.10% | 5.34% | 4.31% | 15.34% | -9.50% | 34.13% | |||||
| 2025 | 18.21% | -2.68% | -5.30% | -3.55% | 2.32% | 14.46% | 1.55% | 42.94% | -0.76% | -0.90% | 0.55% | 8.13% | 91.03% |
| 2024 | -10.37% | 8.50% | -12.50% | -0.04% | -4.30% | 42.28% | 18.60% | 6.31% | -9.53% | -1.38% | 20.18% | -10.54% | 40.07% |
| 2023 | 20.41% | 0.13% | 2.17% | 11.78% | -2.31% | -1.37% | -0.43% | 2.60% | 19.56% | -13.20% | 16.92% | -7.95% | 51.38% |
| 2022 | 19.44% | 24.41% | -7.09% | 7.99% | -1.64% | -16.80% | 28.98% | -0.48% | -15.89% | 7.33% | -17.29% | 4.56% | 22.26% |
| 2021 | 3.78% | 1.32% | 7.95% | -1.41% | -15.35% | 4.53% | -16.43% | 12.46% | 22.58% | -20.28% | -10.39% | 12.09% | -8.65% |
Benchmark Metrics
Mirum Pharmaceuticals, Inc. has an annualized alpha of 47.11%, beta of 0.96, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since July 18, 2019.
- This stock captured 162.95% of S&P 500 Index gains but only 84.14% of its losses - a favorable profile for investors.
- R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 47.11%
- Beta
- 0.96
- R²
- 0.07
- Upside Capture
- 162.95%
- Downside Capture
- 84.14%
Return for Risk
Risk / Return Rank
MIRM ranks 92 for risk / return — above 92% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Mirum Pharmaceuticals, Inc. (MIRM) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MIRM | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.85 | ||
| Sortino ratioReturn per unit of downside risk | +0.74 | ||
| Omega ratioGain probability vs. loss probability | 1.37 | 1.25 | +0.12 |
| Calmar ratioReturn relative to maximum drawdown | 5.14 | 2.00 | +3.14 |
| Martin ratioReturn relative to average drawdown | 11.27 | 8.49 | +2.78 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Mirum Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Mirum Pharmaceuticals, Inc. was 63.78%, occurring on Mar 18, 2020. Recovery took 100 trading sessions.
The current Mirum Pharmaceuticals, Inc. drawdown is 17.59%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-63.78%Mar 2020 | 2mo 19d | 4mo 25d | 7mo 14dDec 2019 - Aug 2020 | COVID crash2020 |
-53.69%Nov 2019 | 3mo 10d | 26d | 4mo 6dAug 2019 - Dec 2019 | — |
-50.92%Nov 2021 | 1y 3mo | 4mo 8d | 1y 7moAug 2020 - Apr 2022 | — |
-40.25%Dec 2022 | 4mo 21d | 5mo 18d | 10mo 9dAug 2022 - Jun 2023 | Bear market2022 |
-33.02%Jun 2022 | 2mo 11d | 1mo 8d | 3mo 19dApr 2022 - Aug 2022 | Bear market2022 |
Drawdown Indicators
| MIRM | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -63.78% | -56.78% | -7.00% |
Max Drawdown (1Y)Largest decline over 1 year | -20.55% | -9.10% | -11.45% |
Max Drawdown (3Y)Largest decline over 3 years | -32.52% | -18.90% | -13.62% |
Max Drawdown (5Y)Largest decline over 5 years | -40.25% | -25.43% | -14.82% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -17.59% | -1.58% | -16.01% |
Average DrawdownAverage peak-to-trough decline | -19.97% | -10.70% | -9.27% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.35% | 2.14% | +7.21% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Mirum Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Mirum Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for MIRM relative to other companies in the Biotechnology industry. Currently, MIRM has a P/S ratio of 14.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MIRM in comparison with other companies in the Biotechnology industry. Currently, MIRM has a P/B value of 25.7. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with MIRM
Add Mirum Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with MIRM